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Abstract: Reducing the incidence of gastrointestinal infections (GIs) that occur at early stages to
mitigate hospitalizations and treatments with adverse effects is a promising strategy for providing
well-being to infants and their families. This systematic review and meta-analysis explores whether
the early administration of Limosilactobacillus fermentum CECT5716 might be effective as a preventive
therapy for GIs. We reviewed the literature to identify randomized controlled trials (RCTs) investi-
gating the effectiveness of milk formulas supplemented with L. fermentum CECT5716 administered
to infants at early stages to reduce the incidence of GIs. The MEDLINE (via PubMed), Web of Science
(WoS), and Cochrane Central Register of Controlled Trials (via CENTRAL) databases were searched
up to 15 June 2021. GI data from the included studies were synthesized in a random-effects model.
Three RCTs were finally selected including 435 infants. There was a significant reduction in the
incidence rate of GIs for those receiving L. fermentum CECT5716 compared with those receiving
placebo (IRR: 0.52, 95% CI: 0.36–0.74, p = 0.0004). Heterogeneity between studies was moderate
(I2 = 54.5%). Based on the present systematic review and meta-analysis, the administration of L.
fermentum CECT5716 at doses from 1 × 109 to 8.4 × 108 cfu/day in milk formulas may prevent GIs
in infants up to 12 months old. Longer-term studies including a higher number of infants are needed
to determine whether the use of this probiotic during the early stages of life is an efficient way to
reduce the incidence of GIs.
Keywords: gastrointestinal infection; diarrhea; formula-fed infant; probiotics; Lactobacillus fermentum;
Limosilactobacillus fermentum
1. Introduction
Although breast milk was once considered a sterile fluid, it is now widely accepted
that it has its own unique microbiome, consisting of many commensal bacteria [1,2]. Most
studies report that the stool microbiota of breastfed infants differs from that of infants fed
formula [3]. The lactic acid bacteria present in human milk, in addition to other bifidogenic
compounds such as oligosaccharides, are transferred from the mother to the infant through
lactation [2], which may, at least in part, be responsible for some of the beneficial effects
observed in breastfed infants [4]. Hence, there is a large body of evidence documenting the
benefits of human breast milk in infants, including reduction of morbidity and mortality
and protection against specific infections during the breastfeeding period [5,6]. This fact is
extremely relevant for public health, because infectious diseases are the most common type
of illness among infants worldwide. Thus, international guidelines recommend exclusive
breastfeeding for all infants in the first six months of life, as it provides the best nutritional
start for infants and promotes their healthy growth and development [7].
Unfortunately, exclusive breastfeeding is not always possible. Accordingly, formula
milks are increasingly being supplemented with probiotics, prebiotics, or symbiotics to
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achieve a similar intestinal microbiota composition in formula-fed infants to in breast-
fed children [4]. The European Society of Pediatric Gastroenterology, Hepatology, and
Nutrition (ESPGHAN) Committee on Nutrition states that supplementation of infant or
follow-on formulas with a few probiotics may be associated with a reduction in the risk of
nonspecific gastrointestinal infections (GIs) as well as antibiotic use [8].
Scientific evidence supporting the use of probiotics for the prevention of infectious
diseases is only emerging, though the results appear to be promising. Previously known as
Lactobacillus fermentum CECT5716, it is currently named, according to the recent nomencla-
ture, Limosilactobacillus fermentum CECT5716 [9]. This probiotic is naturally present in breast
milk [10] and it has been proposed as a probiotic for formula milk due to its safety and
functional [11], anti-infectious [12], immunomodulatory [13], and anti-inflammatory [14,15]
properties. This strain is also able to colonize the mammary gland when administered
orally in a capsule to lactating mothers [16]. Additionally, such supplementation is con-
sidered an efficient strategy for the treatment and prevention of infectious mastitis during
lactation [16–18].
In this study, we thoroughly examined the effect of L. fermentum (CECT5716 Lc40) on
the incidence rate of GIs in infants using a systematic review. Subsequently, we aimed to
statistically guarantee the robustness of the evidence through synthesized the data from
the clinical studies in a meta-analysis.
2. Materials and Methods
This review was conducted following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement (Supplementary Material S1) [19].
2.1. Eligibility Criteria
This work considered randomized controlled trials (RCTs) evaluating the effectiveness
of L. fermentum CECT5716 for the prevention of GIs in infants in comparison with placebo.
To be selected for analysis, studies had to meet the participants, intervention, control,
outcome, and study design (PICOS) criteria [20]. Hence, eligible populations were healthy
female and male infants who were being fed infant formula. Ethnicity was not an inclusion
criterion. All doses and forms of L. fermentum CECT5716 administration were included.
The GI incidence was the main outcome. Regarding the study design, prospective, parallel,
and crossover RCTs were included. The study sample size was not restricted. To be
considered for the full-text screening phase, the abstract had to be available in English or
Spanish. Conference abstracts, case reports, ecological studies, and letters to the editor were
excluded, as were those studies with cohort or case-control design and those analyzing the
effect of other probiotics and/or bioactive compounds as the only intervention.
2.2. Search Strategy
We conducted a systematic, computerized literature search from inception until 15
June 2021 in the following three electronic databases: MEDLINE (via PubMed), Web of Sci-
ence (WoS), and Cochrane Central Register of Controlled Trials (via CENTRAL). We created
a search strategy combining index terms and keywords related to (1) “Lactobacillus fer-
mentum CECT5716, Limosilactobacillus fermentum”, (2) “gastrointestinal infections”, and
(3) “childhood”. No filters were applied to ensure the sensitivity of the search. The detailed
search strategies used for the respective databases are presented in Supplementary Material
S2. The reference lists of the included studies and similar reviews were hand-searched
independently by two reviewers (B.P.-V. and R.B.-R.) to identify additional studies. Finally,
complementary internet searches were conducted, and two trial registries (ClinicalTrials.gov:
http://www.clinicaltrials.gov, accessed on 15 June 2021, and EU Clinical Trials Register:
http://www.clinicaltrialsregister.eu, accessed on 15 June 2021) were additionally revised.
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2.3. Study Selection
After the removal of duplicate studies, titles, abstracts, and full texts were screened
according to the aforementioned selection criteria. Two researchers (B.P.-V. and R.B.-
R.) completed all steps of the screening process independently, and discrepancies were
resolved by discussion; if necessary, another reviewer was consulted (M.O.). During the
full-text screening, a list with references not meeting eligibility criteria was kept, with
notes for the reasons for exclusion. Data on the study design, population characteristics,
exposures, comparator/control groups, outcomes, statistical methods, and results were
assessed independently by two reviewers (B.P.-V. and R.B.-R.). Differences were resolved
by discussion.
2.4. Data Extraction and Assessment of the Risk of Bias
Cochrane Review Manager (RevMan) (Computer program, Version 5.4. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration, 2011) was used for data extrac-
tion. Data for the authors, year of publication, language, study characteristics, participant
description, intervention characteristics, outcomes, and statistical analysis were extracted
independently by two reviewers (B.P.-V. and R.B.-R.). Differences were resolved by discus-
sion. The number of GI events was used as the unit of analysis. For studies with more than
one intervention arm, only arms relevant to the review and meeting the inclusion criteria
were extracted. For missing data, authors of eligible RCTs were contacted via email. The
most relevant data are summarized in Table 1. The reviewers independently, but without
being blinded to the authors or journal, assessed the risk of bias in the studies that met
the inclusion criteria. A summary graphic of the risk of bias assessment was created using
RevMan, Version 5.4 (The Nordic Cochrane Centre, Copenhagen, Denmark), which in-
cludes the following criteria: adequacy of sequence generation, allocation concealment and
blinding of participants, personnel and outcome assessment, extent of loss to follow-up, i.e.,
the proportion of patients for whom the investigators were not able to determine outcomes
(incomplete outcome data), and other biases not classified (e.g., use of invalidated outcome
measures) that must be reported. The classification was low risk of bias or high risk of bias
and unclear bias when the study did not provide sufficient data to assess the bias risk [21].
2.5. Data Synthesis
We pooled data from the trials we judged to be clinically homogeneous using RevMan
5.4, and meta-analyses were performed with STATA v.14.0 software (Stata Corp LLC,
Lakeway Drive, College Station, TX, USA). Dichotomous outcomes from the results of
individual studies and pooled statistics are reported as the incidence rate ratio (IRR)
between experimental and control groups with the 95% confidence interval (95% CI). The
IRR and 95% CI were extracted from individual studies and combined to obtain a pooled
IRR and 95% CI by the generic inverse variance method. As heterogeneity among the
studies was suspected, a random-effects model was applied. Heterogeneity was quantified
by I2 (interpreted as the percentage of the total variation between studies attributable to
heterogeneity rather than to chance). We considered an I2 statistic value of 0% to 40%
as low heterogeneity, 41% to 60% as moderate heterogeneity, 61% to 90% as substantial
heterogeneity, and over 91% as considerable heterogeneity [20].
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Table 1. Summary of characteristics of included studies.
Authors (Year) Study Design Setting N Sample Intervention Time ofIntervention Findings Summary
Gil-Campos et al. (2012) RCT, double blind,controlled, multi-center








Analyzed at the end of






powdered infant formula a
with GOS supplemented or
not with a probiotic strain.
Follow up: 4 visits
Experimental product and
dose L. fermentum CECT5716
(8.4 × 108 cfu/day) b
From 1 to
6 months old
IG: ↓ incidence of GI (IR:
0.082 ± 0.037) vs. CG
(IR: 0.283 ± 0.068)
Maldonado et al. (2012) RCT, double blind,controlled, multi-center
Hospital San Cecilio
(Granada, Spain),







Analyzed at the end of






powdered infant formula a
with GOS supplemented or
not with a probiotic strain.
Follow up: 3 visits
Experimental product and
dose: : L. fermentum
CECT5716 (2 × 108 cfu/day)
From 6 to
12 months old
IG: ↓ incidence of GI (IR:
0.196 ± 0.51) vs. CG (IR:
0.363 ± 0.53)
Maldonado et al. (2019) RCT, double blind,controlled, multi-center





















powdered infant formula a
supplemented or not with a
probiotic strain. Follow up:
6 visits
Experimental product and
dose: : L. fermentum CECT5716
(1 × 109–8 × 108 cfu/day) c
From 1 to
12 months old
IG: ↓ incidence of GI (IR:
0.385 ± 0.077) vs. CG
(IR: 0.689 ± 0.106)
Abbreviations: cfu, colony-forming units; RCT, randomized clinical trial; GOS, galactooligosaccharides; IG, intervention group; CG, control group; IR, incidence rate; GI, gastrointestinal infection. a The standard
powdered infant formula had a nutritional composition in accordance with current EU regulations for both starter and follow-on formula. b Data kindly provided by the authors. c The daily consumption of the
formula corresponded to an average dosage of probiotic bacteria of 1 × 109 cfu/day up to 6 months and 7–8 × 108 cfu/day between 6 and 12 months.
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2.6. Quality of the Evidence
We graded the strength of the body of evidence for the effect of L. fermentum CECT5716
on the incidence rate of GIs in infants using the criteria of the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) method [22], as modified by the
Cochrane Handbook for Systematic Reviews of Interventions [23]. This approach assesses
five key domains: risk of bias, heterogeneity, directness, precision of the evidence, and risk
of publication bias. We separately report the applicability of the body of evidence based on
descriptions of the populations, interventions, comparators, duration of study, and settings
of the included studies. To evaluate publication bias, we intended to use a test for funnel
plot asymmetry offered by [24]; however, publication bias was not formally assessed using
a funnel plot due to the small number of studies (<10) included in the meta-analysis.
3. Results
Figure 1 shows the RCTs retrieved and selected through the literature search. A
total of 68 records were obtained using the equation proposed in the different databases
(MEDLINE, WoS and Cochrane). Following the removal of duplicates, 58 references were
included in the title screening. The topic under review was not addressed by 39 abstracts,
and these studies were therefore excluded. The abstracts of the remaining 19 publications
were screened for eligibility following the PICOS criteria. Articles that did not follow the
PICOS criteria, study protocols, or conference abstracts were excluded. Ultimately, three
publications were considered suitable for a detailed evaluation of full-text reports and
included in the systematic review and meta-analysis [4,25,26].




Figure 1. PRISMA flow diagram illustrating the selection process of included studies. 
3.1. Study Characteristics 
The characteristics of the included RCTs are presented in Table 1. The included ran-
domized trials of a total of 512 infants, of whom 435 were followed up. All included stud-
ies were double-blind, randomized, controlled trials and published in English. All studies 
were conducted in Spain [4,25,26]. Two were published in 2012 [4,24], and the other was 
published in 2019 [25]. All the studies included healthy infants exclusively fed formula, 
with an age ranging from one month [4,25] to six months [24]. The diagnosis of infectious 
disease was made by the pediatrician based on specific symptoms and standardized def-
inition. The primary outcome evaluated in Gil-Campos et al. and in Maldonado et al. 
(2019) was the average weight gain between baseline and four months of age [4,25]. In 
both studies, the incidence of GIs was one of the secondary outcomes, as defined as loose 
or watery stools ≥3 times/day, with or without fever or vomiting [4,25]. However, in Mal-
donado et al. (2012) (infants age: 6–12 months), the incidence of GI (as a primary outcome) 
was the occurrence of loose or watery stool ≥4 times/day, with or without a fever or vom-
iting [24]. 
The daily dose of L. fermentum CECT5716 administrated was 8.4 × 108 colony-forming 
units (cfu) in Gil-Campos et al. [4], 1 × 109 cfu up to six months, and 7–8 × 108 cfu between 
six and 12 months in Maldonado et al. (2019) [25] and 2 × 108 cfu in Maldonado et al. (2012) 
[24]. The duration of the intervention period ranged from five to 11 months. In all the 
Figure 1. PRISMA flow diagram illustrating the selection process of included studies.
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3.1. Study Characteristics
The characteristics of the included RCTs are presented in Table 1. The included
randomized trials of a total of 512 infants, of whom 435 were followed up. All included
studies were double-blind, randomized, controlled trials and published in English. All
studies were conducted in Spain [4,25,26]. Two were published in 2012 [4,24], and the other
was published in 2019 [25]. All the studies included healthy infants exclusively fed formula,
with an age ranging from one month [4,25] to six months [24]. The diagnosis of infectious
disease was made by the pediatrician based on specific symptoms and standardized
definition. The primary outcome evaluated in Gil-Campos et al. and in Maldonado et al.
(2019) was the average weight gain between baseline and four months of age [4,25]. In
both studies, the incidence of GIs was one of the secondary outcomes, as defined as loose
or watery stools ≥3 times/day, with or without fever or vomiting [4,25]. However, in
Maldonado et al. (2012) (infants age: 6–12 months), the incidence of GI (as a primary
outcome) was the occurrence of loose or watery stool ≥4 times/day, with or without a
fever or vomiting [24].
The daily dose of L. fermentum CECT5716 administrated was 8.4× 108 colony-forming
units (cfu) in Gil-Campos et al. [4], 1 × 109 cfu up to six months, and 7–8 × 108 cfu between
six and 12 months in Maldonado et al. (2019) [25] and 2 × 108 cfu in Maldonado et al.
(2012) [24]. The duration of the intervention period ranged from five to 11 months. In
all the studies, L. fermentum CECT5716 was administered as an ingredient of a standard
powdered infant formula with a nutritional composition in accordance with current EU
regulations. Maldonado et al. (2012) [24] and Gil-Campos et al. [4] supplemented infant
formula with galactooligosaccharides (GOSs) (0.4 and 0.3 g/100 mL, respectively) along
with probiotics to provide a symbiotic mixture; their control formula also contained GOSs
in the same amount. Follow-up visits were performed by pediatricians at baseline and
every two months in the case of Gil-Campos et al. and at baseline and every three months
in Maldonado et al. (2012) and (2019) [24,25].
The concentration of the probiotic in the formula was analyzed and confirmed every
two months in the three RCTs. Regarding safety, all formulas were well tolerated, and
compliance was good. Furthermore, no adverse effects related to formula consumption
were reported.
3.2. Overall Results
GI data from the three included studies were synthesized in a random-effects model.
A forest plot shows the results of the analysis, with the sample size and number of GI events
for each group in each study (Figure 2). Additionally, the IRR with 95% CI were noted,
with the incidence rate of GIs being lower in the intervention group in all studies. Pooled
results showed a significant reduction in the incidence rate of GIs in children receiving
L. fermentum CECT5716 with children receiving the placebo (n = 435, IRR: 0.52, 95% CI:
0.36–0.74, p = 0.0004). Heterogeneity between studies was moderate (I2 = 54.5%) (Figure 2).
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3.3. Risk of Bias Assessment
The results of the bias risk assessment of the included studies are summarized in
Figure 3. None of the included studies were rated as having a low risk of bias for all
items of the assessment tool. Two studies received no high risk of bias ratings [4,25]. All
studies were found to have employed adequate random sequence-generation methods
and suitable methodology for the blinding of participants and personnel, clearly described
all missing data (if any), and reported all outcomes (Figure 3). Only one study presented
incomplete information about the blinding of the outcome assessment [4]. In all three
studies, insufficient information on allocation concealment was provided. Finally, one
study presented a high risk of bias because of a lack of declared conflict of interest of one
author who was an employee of the company that funded the RCT [24].
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provide the highest quality of evidence; however, the quality of the body of evidence was
considered moderate. As indicated in the risk of bias assessm nt, only e study presented
one of the evaluat d items as having a high risk of bias; thus, we considered that there
were no limitations that may bias estimat of the treatm nt effect. The number of studies
included in the meta-analysis hi dered the performanc of subgroup analyses to identify a
plausible ex l nation for the m derate ter g neity found, prompting the downgrading
of the strength f the body of evidence from high to moderate. More ver, the evidenc was
direct because all the studies presented data on GI events iagnosed by a pediatrician based
on specific symptoms and standardized definitions. The precision of the effect estimate was
assessed by considering the 95% CI, which was found to be of moderate width. Although
publication bias was not formally assessed using a funnel plot due to the small number
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of studies, there was a low probability of unreported studies due to the specificity of the
review question.
4. Discussion
The current systematic review examined RCTs evaluating the effect of L. fermentum
CECT5716 on the incidence rate of GIs in infants. Meta-analysis showed evidence for
a significant preventive effect of L. fermentum CECT5716 administration against GIs. A
significant reduction of 48% in the incidence rate in infants receiving L. fermentum CECT5716
was reported in comparison with those receiving the placebo (IRR: 0.52, 95% CI: 0.36–0.74,
p = 0.0004). Gil-Campos et al. reported the largest significant finding, with a reduced
incidence of diarrhea of 71% compared with the control group (IRR: 0.29, 95% CI: 0.09–0.83,
p = 0.018) [4]. Furthermore, Maldonado et al. (2012) showed a significant reduction of 46%
compared with controls (IRR: 0.54, 95% CI: 0.31–0.95, p = 0.032) [24]. Finally, Maldonado
et al. (2019) reported similar data, with a reduction of 44% vs. controls (IRR: 0.56, 95% CI:
0.33–0.94, p = 0.014) [25]. Moreover, the lack of a high risk of bias identified during the
assessment increased confidence in the findings of these RCTs.
GI is the major cause of acute diarrhea and has been proposed as an important
target for the beneficial effects of probiotics on pediatric diseases [27,28]. Diarrhea, as
one of the gastrointestinal disorders that commonly occurs, causes distress to infants and
parents and leads to a cascade of discomfort, with repetitive consultations with health care
providers [29]. Diarrhea is a major infectious cause of childhood morbidity and mortality
worldwide [30] with an emotional and economic burden for the families of affected children,
as well as a burden on society [31]. In fact, reports of GIs in many industrialized countries
continue to increase and are largely related to waterborne and foodborne outbreaks [32],
which can cause pediatric caregivers to misuse primary care and GI specialized care,
driving unnecessary investigations and pharmacological treatments [33].
Over the last few years, there have been an increasing appreciation and emphasis
on promoting breast milk feeding to enhance infant health, growth, and development.
Indeed, as a source of commensal bacteria that further enhanced infant health, breast
milk offers further benefits associated with breastfeeding, including protection against
pathogens, promotion of gut colonization by beneficial microbes, and, therefore, reduced
incidences of gastrointestinal disease [34]. The isolation of potential probiotic strains from
milk has been the focus of some investigations [12,35]. Overall, the early stages of life
represent an opportunistic period in which the gut microbiota may be more prone to
changes caused by interventions involving probiotics, prebiotics, or their combinations [36].
Their administration during the perinatal period and lactation to favor infant gut col-
onization with potentially beneficial bacteria has been proposed based on the strength
of evidence that bacteria are transmitted from mother to neonate through direct contact
with the maternal microbiota during birth and through the supply of breast-milk bacteria
during lactation [37,38]. Nevertheless, although probiotics may have preventive or ther-
apeutic effects against diarrhea of various etiologies, not all probiotics are effective, and
physicians must select preparations with proven efficacy [39]. L. fermentum CECT5716 is
a probiotic strain originally isolated from four-day postpartum human milk [40] and is
therefore naturally found in human breast milk. Different mechanisms, including com-
petitive phenomena, production of antibacterial compounds, and improvement of the
immune response, have been attributed to the anti-infectious and bactericidal activities of
L. fermentum CECT5716 [12,13].
Furthermore, the beneficial properties of prebiotics such as oligosaccharides mainly
relay on their ability to modulate the gut microbiota composition and to generate fermenta-
tion products (short-chain fatty acids), providing anti-inflammatory and anti-infectious
properties [41]. The administration of GOS along with the probiotic, both in Gil-Campos
et al. [4] and Maldonado et al. (2012) [25], may explain a synergistic effect enhancing the
beneficial effect of L. fermentum CECT5716. However, it is important to highlight that, in
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these studies, the control formula also presented GOS, and therefore the potential effect
that was observed is, at least mainly, exerted by the probiotic.
Regarding other probiotic strains, controversial findings have been reported. In some
studies, Bifidobacterium animalis subsp. lactis BB-12 was administered (10 billion cfu/day)
to 1-month-old infants for eight months [42] and for two years [43] to evaluate impacts
on the risk of acute infectious diseases. The authors reported no significant differences
compared with controls regarding the incidence of gastrointestinal infections, in accordance
with the findings reported in other RCTs combining B. animalis subsp. lactis BB-12 with
prebiotics [44]. In an RCT involving children aged six to 59 months with severe acute
malnutrition, the combination of B. animalis subsp. lactis and Lactobacillus rhamnosus
(10 billion cfu, 50:50) for 8–12 weeks had no effect on reducing diarrhea episodes during
hospitalization, though it did reduce the number of days with diarrhea by 26% in outpatient
treatment [45]. Other studies administrating the same combination of probiotics did not
report a significant reduction in the incidence of GIs during the first seven months of life
in 2-month-old infants [46] or after six months in infants aged 8 to 14 months [47]. For
Lactobacillus plantarum DSM9843, no beneficial effect was observed for the incidence of
gastrointestinal symptoms in children who were prescribed antibiotics [48]; nor in B. lactis
CNCM I-3446 in C-section delivered infants [49] or combined with oligosaccharides in full-
term infants [50]. Nevertheless, another RCT involving healthy term infants 4 to 10 months
old found that those fed a formula supplemented with L. reuteri or B. lactis BB-12 had fewer
and shorter episodes of diarrhea compared with controls after 12 weeks [51]. Furthermore, a
meta-analysis of three RCTs performed to assess the efficacy of L. rhamnosus administration
to prevent healthcare-associated diarrhea concluded that compared with the placebo,
this probiotic has the potential to reduce the overall incidence of healthcare-associated
diarrhea, including rotavirus gastroenteritis [52]. According to the report published by the
ESPGHAN Committee in 2016, the use of L. rhamnosus is recommended for preventing
antibiotic-associated diarrhea in children [53]. Based on the data presented herein, L.
fermentum CECT5716 is another promising candidate to reduce the incidence of GIs in 1- to
12-month-old infants.
5. Strengths and Limitations
Our systematic review has several strengths. The review was based on the methodol-
ogy developed by Cochrane Collaboration and reported according to the PRISMA state-
ment, and we sought to decrease the risk of bias (i.e., no filters were applied during the
search strategy, attempts to identify unpublished trials). The risk of bias in the included
trials was also assessed. Finally, our review focused on a single probiotic strain; thus,
the findings are clinically relevant and applicable to practice. Nevertheless, the current
meta-analysis has some limitations. First, only a small number of studies were available.
However, all included studies were RCTs with more than 100 participants, which increased
the methodological quality of the body of evidence, as outlined in the GRADE assess-
ment [22]. Second, the unexplained moderate heterogeneity found downgraded the quality
of the evidence. Another limitation is the fact that one of the studies [24] used a different
dose of the probiotic compared to the other two [4,25]. Although some studies found a
relationship between dose and the observed effect for other probiotic strains [54,55], the
results observed in this meta-analysis did not support a dose–response effect for L. fermen-
tum CECT5716. This observation is also in agreement with the nondependent dose effect
exerted by L. fermentum for other applications [16]. Finally, although GI was diagnosed
by a pediatrician in all three studies, the definition of diarrhea was not homogeneous.
Indeed, the Consensus Group on Outcome Measures Made in Pediatric Enteral Nutrition
Clinical Trials (COMMENT) agreed that consensus for a core set of outcomes with agreed
definitions, including those related to acute diarrhea, should be reached and that these
outcomes should be measured and reported in nutritional trials [56].
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6. Implications
In Europe, it is estimated that the incidence of acute GI ranges from 0.5 to 2 episodes
per child per year in those under the age of three [57]. Effective preventive strategies for
this pathology, which is a major reason for hospitalization in this age range, are required
to improve infant health. The data reported are promising, and early administration of L.
fermentum CECT5716 might be effective as a preventive therapy for GI.
Furthermore, breastfed infants have a lower incidence of infections than those fed
with formula. Hence, formula milk is increasingly being supplemented with probiotics,
prebiotics, or symbiotics to achieve an intestinal microbiota in formula-fed infants similar
to that in breastfed infants. The current meta-analysis strengthens the evidence with regard
to the effect of formula milk supplemented with L. fermentum CECT5716 for preventing
GIs in infants from birth to one year of life. Additionally, this supplementation has been
demonstrated to be well tolerated and without adverse effects. Nevertheless, given the
study population, more evidence is necessary. Further studies including groups with a
larger number of infants and longer time periods are recommended for applying specific
recommendations. Follow-up studies will also be useful to guarantee the effect and safety.
Only Gil-Campos et al. performed follow-up to evaluate long-term effects after three
years [58]. The authors declared that early administration was safe, with no differences in
infection incidence in comparison to control formula during the follow-up period. Thus,
future RCTs should include subsequent monitoring after the intervention.
7. Conclusions
The findings of this systematic review and meta-analysis suggest a beneficial effect of
L. fermentum CECT5716, a probiotic strain naturally found in breast milk, on the prevention
of GIs in infants up to 12 months old. The use of a milk formula containing doses from
1 × 109 to 8.4 × 108 cfu/day of this probiotic reduces the incidence of diarrhea events
without causing adverse events. As only three RCTs have been performed thus far, further
studies including a larger number of infants and a longer time period should be performed
to determine whether the use of this strain during an early stage of life is an efficient
preventive measure to reduce the incidence of GIs and to address specific recommendations.
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